Hair analysis may help determine drug levels, adherence and virological response
1 December 2002. Related: Antiretrovirals.
Antiretrovirals
Disadvantage from prior nucleoside therapy persists for years during HAART
1 December 2002. Related: Antiretrovirals.
BMS experimental PI atazanavir shows potency comparable to NNRTI efavirenz among treatment-naïve HIV patients
13 November 2002. Related: Conference reports, Antiretrovirals.
New evidence favours routine measurement of plasma concentrations in salvage therapy to maintain sustained drug levels
13 November 2002. Related: Antiretrovirals.
New safety information for ddI used with ribavirin
13 November 2002. Related: Treatment alerts, Antiretrovirals.
US FDA issues new safety information for tenofovir co-administration with ddI
13 November 2002. Related: Treatment alerts, Antiretrovirals.
European Commission approves new boosted saquinavir regimen (1000 mg saquinavir/100 mg ritonavir twice daily) for the treatment of HIV-1
13 November 2002. Related: Antiretrovirals.
US HIV community hold productive meeting with Schering-Plough on new anti-HIV entry inhibitors SCH-C and SCH-D
13 October 2002. Related: Antiretrovirals.
Notes on Schering-Plough/HIV community meeting held August 28 2002
13 October 2002. Related: Antiretrovirals.
US FDA announces important changes in amprenavir product labelling
13 October 2002. Related: Antiretrovirals, PK and drug interactions.
Much lower dose of lamivudine needed for HIV-positive patients on dialysis
13 October 2002. Related: Antiretrovirals.
Patients discontinuing HAART must be carefully monitored
13 October 2002. Related: Antiretrovirals.
New anti-HIV compounds discussed at the Seville HIV Drug Resistance Workshop and the Barcelona World AIDS Conference
11 September 2002. Related: Conference reports, Antiretrovirals.
Management of people with treatment experience and drug resistance
11 September 2002. Related: Conference reports, Antiretrovirals.
Lopinavir/r exhibits sustained virologic response in antiretroviral-naïve patients: 3-year data
11 September 2002. Related: Conference reports, Antiretrovirals.
Patients will have options regarding T-20 (enfuvirtide) injection sites
11 September 2002. Related: Conference reports, Antiretrovirals.
The role of tenofovir in antiretroviral-naive patients
11 September 2002. Related: Conference reports, Antiretrovirals.
New data from clinical trials of antiretrovirals
11 September 2002. Related: Conference reports, Antiretrovirals.
Trial supports lopinavir/ritonavir as first-line therapy in HIV infection
11 September 2002. Related: Antiretrovirals.
Ritonavir has anti-neoplastic effects independent of HIV inhibition
11 September 2002. Related: Antiretrovirals.
Pharmacokinetics and further benefits of therapeutic drug monitoring (TDM)
11 September 2002. Related: Antiretrovirals.
BMS advice on interaction between didanosine EC and tenofovir
11 July 2002. Related: Treatment alerts, Antiretrovirals.
Optimal antiretroviral drug levels improve outcomes
11 July 2002. Related: Antiretrovirals.
Roche and Trimeris announce 24-week results from second pivotal study of HIV fusion inhibitor T-20
11 July 2002. Related: Antiretrovirals.
New study adds to evidence showing adherence is linked to survival
11 July 2002. Related: Antiretrovirals.
Intermittent use of ART is associated with increased mortality
11 July 2002. Related: Antiretrovirals.
Amprenavir mutations may significantly affect LPV resistance
11 June 2002. Related: Antiretrovirals, Drug resistance.
24-week results from phase III study of HIV fusion inhibitor T-20
11 June 2002. Related: Antiretrovirals.
Abacavir treatment limited by prior NRTI exposure
11 June 2002. Related: Antiretrovirals, Drug resistance.
Hydroxyurea: in vitro evidence of potency against HIV viral reservoirs
11 May 2002. Related: Antiretrovirals.
Transient increases in viral load are common among people on HAART, finds a study of UK patients
11 May 2002. Related: Antiretrovirals.
Meta-analysis supports triple therapy for HIV infection
11 May 2002. Related: Antiretrovirals.
New drugs: perhaps some genuine excitement this time
10 April 2002. Related: Conference reports, Antiretrovirals.
T20 and beyond: inhibition of HIV attachment and fusion at the 9th CROI
10 April 2002. Related: Conference reports, Antiretrovirals.
Pharmacogenetics predict abacavir hypersensitivity
10 April 2002. Related: Conference reports, Antiretrovirals.
Hepatic injury with nevirapine related to drug level and hepatitis C infection
10 March 2002. Related: Antiretrovirals, Side effects.
Study finds that PI-containing regimens have a beneficial effect on oral candidiasis independent of any immune reconstitution
10 March 2002. Related: Antiretrovirals, Coinfections and complications.
Tenofovir DF approved for marketing in European Union
10 March 2002. Related: Antiretrovirals.
It may be important to screen and treat riboflavin deficiency in patients on nucleoside analogues
10 March 2002. Related: Antiretrovirals, Side effects.
Factors associated with immunologic stability despite protease inhibitor based HAART “failure”
10 March 2002. Related: Antiretrovirals.
NIAID funds 9-year, 6,000-participant study to look at how best to use antiretrovirals
10 March 2002. Related: Antiretrovirals.
Impaired response to HAART found in HIV-positive individuals with high autonomic nervous system activity
10 January 2002. Related: Antiretrovirals.
Anti-HIV effects of the malarial drug chloroquine
10 January 2002. Related: Antiretrovirals.
Treatment guidelines should place more emphasis on CD4+ counts than on viral loads
10 January 2002. Related: Antiretrovirals.
Impact of Kaletra on amprenavir plasma concentrations in HIV treatment-experienced patients
9 January 2002. Related: Conference reports, Antiretrovirals.
ddI EC (Videx) study confirms and clarifies dosing on an empty stomach
9 January 2002. Related: Conference reports, Antiretrovirals.
Swatch study: should we be cycling drugs?
9 January 2002. Related: Conference reports, Antiretrovirals.
New HIV drugs, resistance, pharmacogenomics
9 January 2002. Related: Conference reports, Antiretrovirals.
Antiretroviral therapy
9 January 2002. Related: Conference reports, Antiretrovirals.
Delaying antiretroviral therapy may be considered for many patients
9 December 2001. Related: Antiretrovirals.
Correlation between reduction in plasma HIV1 RNA concentration 1 week after start of antiretroviral treatment and longerterm efficacy
9 December 2001. Related: Antiretrovirals.
One week on, one week off experimental regimen might reduce the cost and toxicities of HIV therapy
9 December 2001. Related: Antiretrovirals.
Enteric coated didanosine significantly reduces nausea, bloating, GI upset
9 December 2001. Related: Antiretrovirals, Side effects.
Secondary mutations in HIV-1 protease predict treatment failure in naive patients
9 December 2001. Related: Antiretrovirals, Drug resistance.
Antiretroviral regimen complexity, self-reported adherence, and HIV patients’ understanding of their regimens: survey of women in the HERS study
9 December 2001. Related: Antiretrovirals.
Study indicates NNRTI mutations have little effect upon HIV-1 replicative capacity
9 December 2001. Related: Antiretrovirals.
Tenofovir DF 907 study
2 November 2001. Related: Conference reports, Antiretrovirals.
The Max Cmin 1 trial: indinavir/ritonavir vs. saquinavir/ritonavir
2 November 2001. Related: Conference reports, Antiretrovirals.
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV cohort study
2 November 2001. Related: Antiretrovirals, Side effects.
European CPMP gives positive opinion for European licensing of tenofovir DF
2 November 2001. Related: Antiretrovirals.
EC approves abacavir for use by HIV-infected children
2 November 2001. Related: Antiretrovirals, Paediatric care.
Report on salvage therapy from the 39th annual meeting of the IDSA
2 November 2001. Related: Antiretrovirals, Drug resistance.
Tenofovir DF: results from phase III study released
1 October 2001. Related: Antiretrovirals.
US FDA committee recommends approval for tenofovir
1 October 2001. Related: Antiretrovirals.
HIV suppression in lymphoid tissue varies with antiretroviral regimen
1 October 2001. Related: Antiretrovirals.